

Please type a plus sign (+) inside this box ☐

Attorney Docket **P1747R2D1**  
PATENT

**EV 351927905 US:** Express Mail Number

**September 5, 2003:** Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Mail Stop PATENT APPLICATION  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**NON-PROVISIONAL APPLICATION TRANSMITTAL UNDER 37 CFR 1.53(b)**

Transmitted herewith for filing is a non-provisional patent application:

Inventor(s) (or Application "Identifier"):

**Marvin R. Garovoy, San Anselmo, California**  
**Susan M. Kramer, San Francisco, California**  
**Russell L. Dedrick, Kensington, California**  
**Karen Starko, Hillsborough, California**

Title: **TREATMENT OF LFA-1 ASSOCIATED DISORDERS WITH INCREASING DOSES**

**1. Type of Application**

- ☐ This application is for an original, non-provisional application.
- ☐ This is a non-provisional application claiming priority to provisional application no. \_\_, filed \_\_, the entire disclosure of which is hereby incorporated by reference.
- ☒ This is a ☐ continuation-in-part ☐ continuation ☒ divisional application claiming priority to application Serial Number 09/936,603, filed February 11, 2002, which claims priority to international patent application no. PCT/US00/07189, filed March 17, 2000, which claims the benefit of U.S. non-provisional patent application no. 09/273,043, filed March 19, 1999 and of provisional patent applications no. 60/125,351 and 60/125,228, both filed March 19, 1999, the entire disclosures of which are hereby incorporated by reference.

**2. Papers Enclosed Which Are Required For Filing Date Under 37 CFR 1.53(b) (Non-provisional )**

25 pages of specification  
1 pages of claims  
1 page(s) of abstract  
10 sheet(s) of drawings  
☒ formal ☐ informal

22388 U.S. PTO

10/655905



09/05/03

**3. Declaration or Oath**

\_\_\_\_\_ *(for new and CIP applications; also for Cont./Div. where inventor(s) are being added)*  
An executed declaration of the inventor(s) ☐ is enclosed ☐ will follow.

  X   *(for Cont./Div. where inventorship is the same or inventor(s) being deleted)*  
A copy of the executed declaration/oath filed in the prior application is enclosed  
(37 CFR 1.63(d)).

\_\_\_\_\_ *(for Cont./Div. where inventor(s) being deleted)*  
A signed statement is attached deleting inventor(s) named in the prior  
application (see 37 CFR 1.63(d)(2) and 1.33(b)).

**4. Assignment**

\_\_\_\_\_ *(for new and CIP applications)*  
An Assignment of the invention to GENENTECH, INC. ☐ is enclosed with  
attached Recordation Form Cover Sheet ☐ will follow.

  X   *(for cont./div.)*  
The prior application is assigned of record to Genentech, Inc. and XOMA Ltd.

**5. Amendments (for continuation and divisional applications)**

\_\_\_\_\_ Cancel in this application original claims \_\_ of the prior application before calculating the filing  
fee. (At least one original independent claim must be retained for filing purposes.)

\_\_\_\_\_ A preliminary amendment is enclosed. (Claims added by this amendment have been  
properly numbered consecutively beginning with the number next following the highest  
numbered original claim in the prior application.)

**6. Fee Calculation (37 CFR 1.16)**

The fee has been calculated as follows:

CLAIMS FOR FEE CALCULATION					
Number Filed		Number Extra		Rate	Basic Fee 37 CFR 1.16(a)
					\$750.00
Total Claims	15	- 20 =	0	X \$18.00	\$0.00
Independent Claims	1	- 3 =	0	X \$84.00	\$0.00
Multiple dependent claim(s), if any				+ \$280.00	\$0.00
Filing Fee Calculation					\$750.00

**7. Method of Payment of Fees**

The Commissioner is hereby authorized to charge Deposit Account No. 07-0630 in the amount of \$750.00. **A duplicate copy of this transmittal is enclosed.**

**8. Authorization to Charge Additional Fees**

The Commissioner is hereby authorized to charge any additional fees required under 37 CFR §1.16 and 1.17, or credit overpayment to Deposit Account No. 07-0630. **A duplicate copy of this transmittal is enclosed.**

**9. Additional Papers Enclosed**

- ☒ Information Disclosure Statement (37 CFR §1.98) w/ PTO-1449 and citations
- ☐ Submission of "Sequence Listing", computer readable copy, certificate re: sequence listing, and/or amendment pertaining thereto for biological invention containing nucleotide and/or amino acid sequence.
- ☐ A new Power of Attorney or authorization of agent.
- ☒ Other: Application Data Sheet

**10. Maintenance of Copendency of Prior Application (for continuation and divisional applications)**

*[This item must be completed and the necessary papers filed in the prior application if the period set in the prior application has run]*

- \_\_\_\_\_ A petition, fee and/or response has been filed to extend the term in the pending prior application until
- \_\_\_\_\_ A copy of the petition for extension of time in the **prior** application is attached.

**11. Correspondence Address:**

X Address all future communications to:

Attn: Lee K. Tan, Ph.D.  
Customer No: 09157

Respectfully submitted,  
GENENTECH, INC.

Date: September 5, 2003

By: Lee Tan  
Lee K. Tan, Ph.D.  
Reg. No. 39,447  
Telephone No. (650) 225-4462

**CUSTOMER NO: 09157**